Decision tree

Results: 886



#Item
721Artificial intelligence / Data mining / Decision tree learning / Machine learning / T-tree / Tree / R-tree / Phylogenetic tree / Computational statistics / Binary trees / Graph theory / Phylogenetics

PDF Document

Add to Reading List

Source URL: www-stat.wharton.upenn.edu

Language: English - Date: 2008-09-21 11:54:31
722Decision trees / Econometrics / Statistical models / Ensemble learning / Gradient boosting / Backfitting algorithm / Normal distribution / Decision tree learning / Errors and residuals in statistics / Statistics / Regression analysis / Machine learning

PDF Document

Add to Reading List

Source URL: www-stat.wharton.upenn.edu

Language: English - Date: 2008-09-21 11:42:44
723Machine learning / Estimation theory / Linear regression / Binary tree / Decision tree learning / Tree / Statistics / Econometrics / Regression analysis

PDF Document

Add to Reading List

Source URL: www-stat.wharton.upenn.edu

Language: English - Date: 2008-09-21 11:59:07
724Artificial intelligence / Decision tree learning / Random forest / Supervised learning / Recursive partitioning / Statistical classification / Semiconductor device fabrication / Machine learning / Decision trees / Computational statistics

PDF Document

Add to Reading List

Source URL: www.amstat.org

Language: English - Date: 2005-09-07 21:47:05
725Organic anion transporter 1 / Solute carrier family / Chemistry / Didanosine / IC50 / Investigational New Drug / Metformin / Pharmacology / Medicine / Bristol-Myers Squibb

Decision tree to determine whether an investigational drug is an inhibitor of OCT2, OAT1, or OAT3 and when an in vivo clinical study is needed — (Modified From Figures in Giacomini KM, et al, Nat. Rev Drug Discov. 9: 2

Add to Reading List

Source URL: www.fda.gov

Language: English
726Gene delivery / Transfection / Biology / Molecular biology / Biochemistry

Figure 10: Decision tree to determine whether an investigational drug is a substrate for OCT2, OAT1, or OAT3 and when an in vivo clinical study is needed —(Modified From Figures in Giacomini KM, et al, Nat. Rev Drug Di

Add to Reading List

Source URL: www.fda.gov

Language: English
727IC50 / Pharmacodynamics

Figure 7: Decision tree to determine whether an investigational drug is an inhibitor of P-gp and when an in vivo clinical study is needed. A similar model can be applied to a BCRP inhibitor) — (Modified From Figures in

Add to Reading List

Source URL: www.fda.gov

Language: English
728Statins / Organic chemistry / Rosuvastatin / IC50 / Pitavastatin / Pravastatin / Chemistry / Carboxylic acids / Diols

Figure 9: Decision tree to determine whether an investigational drug is an inhibitor of OATP1B1 or OATP1B3 and when an in vivo clinical study is needed —(Modified From Figures in Giacomini KM, et al, Nat. Rev Drug Disc

Add to Reading List

Source URL: www.fda.gov

Language: English
729Biomolecules / Catalysis / Pharmacokinetics / Metabolism / Enzyme / In vitro / In vivo / Cytochrome P450 / Simcyp Simulator / Chemistry / Pharmaceutical sciences / Pharmacology

Figure 1. Metabolism-Based Drug-Drug Interaction Studies — Decision Tree Conduct In Vitro Metabolism and Drug-Drug Interaction Studies in Human Tissuesa - Phase I enzymes: CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A, others

Add to Reading List

Source URL: www.fda.gov

Language: English
730Molecular biology / Gene delivery / Transfection

Figure 8: Decision tree to determine whether an investigational drug is a substrate for OATP1B1 or OATP1B3 and when an in vivo clinical study is needed— (Modified From Figures in Giacomini KM, et al, Nat. Rev Drug Disc

Add to Reading List

Source URL: www.fda.gov

Language: English
UPDATE